Haemochromatosis-associated HFE genotypes in English blood donors: Age-related frequency and biochemical expression

Journal of Hepatology

Volumn 39, Issue 6, 2003, Pages 925-931

  Chambers, Vanessa ^a   Sutherland, Lindsey ^a   Palmer, Karren ^a   Dalton, Ann ^a   Rigby, Alan S ^a   Sokol, Robert ^b   Pollitt, Rodney ^a   Tanner, Stuart ^a   Gleeson, Dermot ^c,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Blood donors; Genetics; Haemochromatosis; Iron indices

Indexed keywords

FERRITIN; IRON;

ADULT; AGE; ALLELE; ARTICLE; BLOOD DONOR; C282Y GENE; CONTROLLED STUDY; FERRITIN BLOOD LEVEL; GENE; GENOTYPE; H63D GENE; HEMOCHROMATOSIS; HETEROZYGOSITY; HFE GENE; HOMOZYGOSITY; HUMAN; IRON DEFICIENCY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION;

EID: 0346873990     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00471-9     Document Type: Article

References (38)

1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
2. M W, JD S, DF W, Merryweather-Clarke AT. A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997;41:841-4
3. Jazwinska EC, Cullen LM, Busfield F, Pyper WR, Webb SI, Powell LW, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-251.
4. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999;116:372-377.
5. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998;114:319-323.
6. Bomford A. Genetics of haemochromatosis. Lancet 2002;360:1673-1681.
7. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-278.
8. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4:183-198.
9. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. J Am Med Assoc 2001;285:2216-2222.
10. Merryweather-Clarke AT, Worwood M, Parkinson L, Mattock C, Pointon JJ, Shearman JD, et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 1998;101:369-373.
11. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998;43:830-836.
12. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-724.
13. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5211 voluntary blood donors. Hepatology 2000;31:1160-1164.
14. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001;114(2):474-484.
15. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-337.
16. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G to A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218.
17. Santos M, Clevers HC, Marx JJ. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N Engl J Med 1997;336:1327-1328.
18. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-323.
19. Bonkovsky H, M P-F, N P, al. e. Porphyria cutanea tarda, hepatitis C and HFE gene mutations in North America. Hepatology 1998;27:1661
20. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
21. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
22. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation 1999;100:1274-1279.
23. Sullivan JL. Iron and the genetics of cardiovascular disease. Circulation 1999;100:1260-1263.
24. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, et al. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 2001;22:563-568.
25. Datz C, Haas T, Rinner H, Sandhofer F, Patsch W, Paulweber B. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem 1998;44:2429-2432.
26. Liu Q, Thorland EC, Heit JA, Summer SS. Overlapping PCR for bidirectional PCR amplification of specific alleles: a rapid one-tube method for simultaneously differentiating homozygotes and heterozygotes. Genetic Res 1997;7:389-398.
27. Ferrie RM, Schwartz M, Robertson-Vaudin S, Super M, Malone G, Little S. Development, multiplexing and applications of the ARMS test for common mutations of the CFTR gene. Am J Hum Genet 1992;51:251-262.
28. Lee WC, Hsiao CK. Alternative summary indices for the receiver operating characteristic curve. Epidemiology 1996;7:605-611.
29. Miedzybrodzka Z, Loughlin S, Baty D, Terron A, Kelly K, Dean J, et al. Haemochromatosis mutations in North-East Scotland. Br J Haematol 1999;106:385-387.
30. Bathum L, Christiansen F, Nybo H, Ranberg K, Gaist D, Jeune B, et al. Association of mutations in the haemochromatosis gene with shorter life expectancy. Arch Intern Med 2001;161:2441-2444.
31. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
32. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25(1):162-166.
33. Barton JC, Preston BL, McDonnell SM, Rothenberg BE. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 2001;41:123-129.
34. Flesland O. Ferritin concentration in serum in health adults. Significance for blood donation. Tidsskr Nor Laegeforen 1992;112:1950-1951.
35. Milman N. Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Int J Hematol 1996;63:103-135.
36. Milman N, Sondergaard M. Iron stores in male blood donors evaluated by serum ferritin. Transfusion 1984;24:464-468.
37. Hernandez Lamas MC, Lopez Perez-Lanzac JC, Prat Arrojo I, Sanchez Gordo F, Arleth Christensen E, Sanchez Font E. Determination of serum ferritin: ideas for avoiding induced ferropenia in blood donors. Sangre (Barc) 1994;39:9-14.
38. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-1805.